Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Marion FerreiraAurélie SwalduzLaurent GreillierPauline du RusquecHubert CurcioJudith RaimbourgAnne-Claire ToffartValérie GounantSebastien CouraudGonzague De ChabotSylvie FriardJosé HureauxGaëlle JeanninLuc OdierCharles RicordelMarie WislezClotilde DescarpentriesGuillaume HerbreteauPascale MissyFranck MorinVirginie WesteelAlexis B Cortot

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

In this large real-world study of METex14 NSCLC patients, the efficacy of capmatinib was confirmed, with a manageable safety profile, even in patients with brain metastases and in those who received several lines of treatment. This study reinforces the key role of capmatinib for these patients.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
chronic kidney disease
brain metastases
prognostic factors
stem cells
patient reported outcomes
bone marrow
advanced non small cell lung cancer